Crystal's Coder Hub👁️ ICD-10 CM H34.8110 — Central Retinal Vein Occlusion, Right Eye, With Macular Edema
Billable Code Confirmed
ICD-10 CM H34.8110 is a fully billable 7-character ICD-10-CM code valid for FY2026 (October 1, 2025 – September 30, 2026). The 6th character (1) specifies right eye laterality; the 7th character (0) specifies the clinical disease state with macular edema, distinguishing this code from its right-eye siblings H34.8111 (with retinal neovascularization) and H34.8112 (stable). All three characters in positions 5–7 are required for a valid, reimbursable claim; the parent H34.811 (Central retinal vein occlusion, right eye) is a non-billable header code and must never be submitted.
Non-Billable Parent Codes
H34.811 — Central retinal vein occlusion, right eye — is a non-billable parent code first converted from billable to non-billable in FY2017 when the 7th character disease-state axis was added; submitting it will generate a claim rejection. H34.81 — Central retinal vein occlusion (no laterality specified) — is non-billable, lacking both the laterality and disease-state characters required for specificity. H34.8 — Other retinal vascular occlusions — is the non-billable category header encompassing central vein, tributary (branch) vein, and venous engorgement subcategories; it must never be billed.
Clinical Context
ICD-10 CM H34.8110 captures the active, vision-threatening phase of CRVO in the right eye in which VEGF-driven fluid accumulation within the macula is the dominant clinical finding and the primary treatment target. This is the code that triggers treatment authorization: intravitreal anti-VEGF therapy (ranibizumab, aflibercept, bevacizumab, brolucizumab) or corticosteroid implant (dexamethasone/Ozurdex, fluocinolone acetonide) is standard of care when this phenotype is present and confirmed on OCT. The distinction from H34.8111 (with retinal neovascularization) is clinically significant — neovascularization indicates ischemic CRVO with higher risk of neovascular glaucoma and vitreous hemorrhage, while macular edema may occur in both ischemic and non-ischemic subtypes.
Code Classification
ICD-10 CM H34.8110 is an ICD-10-CM diagnosis code and must appear in the diagnosis fields of the claim — never in the procedure field. In the inpatient facility setting, this diagnosis code must be paired with the appropriate ICD-10-PCS Administration code (e.g.,
3E0C3GCfor intravitreal anti-VEGF injection) when a qualifying procedure is performed during the admission. Submitting the diagnosis code in the procedure field of a UB-04 or 837I transaction constitutes a claim error.
🔍 Code Description
ICD-10 CM H34.8110 classifies central retinal vein occlusion (CRVO) of the right eye in its most clinically active and vision-threatening form — the stage defined by macular edema. In CRVO, obstruction of the central retinal vein, typically at the level of the lamina cribrosa where the vein shares a rigid fibrovascular sheath with the central retinal artery, leads to venous stasis, elevated capillary pressure, and breakdown of the inner blood-retinal barrier. The resulting release of vascular endothelial growth factor (VEGF) and inflammatory cytokines drives fluid leakage into the retinal layers of the macula, producing characteristic cystoid intraretinal spaces, subretinal fluid, and diffuse thickening measurable on spectral-domain optical coherence tomography (SD-OCT). This macular thickening — quantified as central subfield thickness (CST) in micrometers — is the principal cause of visual acuity loss in CRVO and the primary target of modern pharmacotherapy.
CRVO is the second most common retinal vascular disorder after diabetic retinopathy, affecting patients most frequently over age 50 with systemic vascular risk factors — essential hypertension (I10) being the most prevalent, followed by hyperlipidemia, type 2 diabetes mellitus (E11.9), and hypercoagulable states. On fundus examination, the classic CRVO picture includes flame-shaped and dot/blot retinal hemorrhages distributed in all four quadrants, disc edema, and dilated tortuous retinal veins. If untreated, persistent macular edema causes irreversible photoreceptor damage and central vision loss; in ischemic forms, retinal nonperfusion drives downstream neovascularization (H34.8111), placing the eye at risk for neovascular glaucoma (H40.5110), vitreous hemorrhage (H43.11), and tractional retinal detachment.
🌳 Code Tree / Hierarchy
H34 — Retinal vascular occlusions ❌ Non-billable
│
├── H34.0 — Transient retinal artery occlusion ❌ Non-billable
│ ├── H34.01 …… right eye ✅ Billable
│ ├── H34.02 …… left eye ✅ Billable
│ └── H34.03 …… bilateral ✅ Billable
│
├── H34.1 — Central retinal artery occlusion ❌ Non-billable
│ ├── H34.10 …… unspecified eye ✅ Billable
│ ├── H34.11 …… right eye ✅ Billable
│ └── H34.12 …… left eye ✅ Billable
│
├── H34.2 — Other retinal artery occlusions ❌ Non-billable
│ └── H34.23 — Retinal artery branch occlusion ❌ Non-billable
│ ├── H34.231 …… right eye ✅ Billable
│ ├── H34.232 …… left eye ✅ Billable
│ └── H34.233 …… bilateral ✅ Billable
│
├── H34.8 — Other retinal vascular occlusions ❌ Non-billable
│ │
│ ├── H34.81 — Central retinal vein occlusion ❌ Non-billable
│ │ │
│ │ ├── H34.811 — Central retinal vein occlusion, right eye ❌ Non-billable
│ │ │ ├── H34.8110 …… with macular edema ✅ ◀ THIS CODE
│ │ │ ├── H34.8111 …… with retinal neovascularization ✅ Billable
│ │ │ └── H34.8112 …… stable ✅ Billable
│ │ │
│ │ ├── H34.812 — Central retinal vein occlusion, left eye ❌ Non-billable
│ │ │ ├── H34.8120 …… with macular edema ✅ Billable
│ │ │ ├── H34.8121 …… with retinal neovascularization ✅ Billable
│ │ │ └── H34.8122 …… stable ✅ Billable
│ │ │
│ │ ├── H34.813 — Central retinal vein occlusion, bilateral ❌ Non-billable
│ │ │ ├── H34.8130 …… with macular edema ✅ Billable
│ │ │ ├── H34.8131 …… with retinal neovascularization ✅ Billable
│ │ │ └── H34.8132 …… stable ✅ Billable
│ │ │
│ │ └── H34.819 — Central retinal vein occlusion, unspecified eye ❌ Non-billable
│ │ ├── H34.8190 …… with macular edema ✅ Billable
│ │ ├── H34.8191 …… with retinal neovascularization ✅ Billable
│ │ └── H34.8192 …… stable ✅ Billable
│ │
│ ├── H34.82 — Venous engorgement ❌ Non-billable
│ │ ├── H34.821 …… right eye ✅ Billable
│ │ ├── H34.822 …… left eye ✅ Billable
│ │ └── H34.823 …… bilateral ✅ Billable
│ │
│ └── H34.83 — Tributary (branch) retinal vein occlusion ❌ Non-billable
│ ├── H34.831 — right eye ❌ Non-billable
│ │ ├── H34.8310 …… with macular edema ✅ Billable
│ │ ├── H34.8311 …… with retinal neovascularization ✅ Billable
│ │ └── H34.8312 …… stable ✅ Billable
│ └── (H34.832 left, H34.833 bilateral, H34.839 unspecified — same structure)
│
└── H34.9 — Unspecified retinal vascular occlusion ✅ Billable
7th Character Encodes Current Disease State — Not Historical Diagnosis
The 7th character in the H34.811x–H34.819x family is encounter-specific and reflects the clinician’s documented assessment at the time of the visit — not the initial CRVO diagnosis. H34.8110 = active fluid accumulation in the macula, anti-VEGF treatment-eligible. H34.8111 = ischemic CRVO with neovascularization, proliferative risk. H34.8112 = resolved or quiescent, no active edema or NV. A patient may correctly carry different 7th characters across successive encounters as the disease responds to treatment or progresses. If documentation does not specify the current state, a CDI query is required before code assignment — the coder may not independently infer stability from the absence of a notation.
Tip
Bilateral CRVO (H34.8130) is uncommon but occurs in hypercoagulable states such as antiphospholipid syndrome, polycythemia vera, hyperviscosity syndromes, and Behçet disease. When bilateral CRVO with macular edema is confirmed in both eyes, assign the single bilateral code rather than two separate laterality codes — the bilateral code captures the full clinical picture and avoids duplicate-laterality edits on the claim.
✅ Includes
- Central retinal vein occlusion with cystoid macular edema, right eye — macular edema described as cystoid, diffuse, or subfoveal, secondary to CRVO in the right eye, is captured under H34.8110 regardless of morphologic descriptor.
- CRVO-associated macular thickening, right eye — documentation using “macular thickening,” “macular swelling,” or “increased central subfield thickness due to CRVO” maps to this code when the underlying cause is confirmed as central retinal vein occlusion.
- Non-ischemic and ischemic CRVO with macular edema, right eye — H34.8110 does not distinguish between ischemic and non-ischemic subtypes; both are captured here when the 7th-character disease state is macular edema.
- Post-treatment CRVO, right eye, with residual or recurrent macular edema — if macular edema persists or recurs following anti-VEGF or steroid therapy and the clinician documents active edema at the current encounter, H34.8110 remains appropriate.
❌ Excludes
Excludes 1
Excludes 1 — Amaurosis Fugax ( G45.3)
ICD-10 CM H34.8110 and G45.3 (Amaurosis fugax) are mutually exclusive under a Type 1 Excludes note at the H34 category level. Amaurosis fugax represents transient monocular visual loss lasting seconds to minutes that fully resolves, caused by transient retinal ischemia rather than a fixed venous occlusion. If a clinician documents transient visual loss in the right eye that resolves completely, G45.3 is the correct code and H34.8110 must not be assigned. If the patient has both a known CRVO and a new episode of transient visual loss in the same eye, a CDI query should clarify whether the events are distinct before assigning either code.
Excludes 2
There are no Excludes 2 notations specific to H34.8110. The systemic conditions driving CRVO — hypertension, diabetes, hypercoagulable states — are separately codeable and should be captured as additional diagnoses on every encounter where they are documented. The chapter-level note for H00–H59 instructs coders to apply an external cause code following the eye condition code when a causal external mechanism is applicable.
📋 Clinical Overview
CRVO 7th-Character Subtype Comparison — Right Eye (H34.811x)
The three right-eye CRVO codes share the same central venous occlusion at the disc level but differ in the dominant clinical manifestation documented at the current encounter. The 7th character is assigned to the present disease state — not the historical presentation — making the subtype assignment encounter-specific and potentially transitioning over the course of care.
| Feature | H34.8110 — This Code | H34.8111 | H34.8112 |
|---|---|---|---|
| 7th Character | 0 — With macular edema | 1 — With retinal neovascularization | 2 — Stable |
| Clinical State | Active fluid within macular layers documented on OCT or clinical exam; CST typically >250–300 µm; cystoid spaces or subretinal fluid may be present | New abnormal vessels at disc (NVD) or retina (NVE) on clinical exam or FA; indicates ischemic CRVO with proliferative risk; macular edema may co-exist | No active macular edema and no neovascularization at current encounter; CRVO resolved, treated to quiescence, or in inactive phase |
| Treatment Trigger | Intravitreal anti-VEGF (ranibizumab, aflibercept, bevacizumab) or intravitreal corticosteroid implant; OCT monitoring each visit | Anti-VEGF plus consideration of panretinal photocoagulation (PRP); urgent assessment for neovascular glaucoma (H40.5110) | Observation and periodic OCT monitoring; no anti-VEGF or laser typically indicated in the absence of active findings |
| Inpatient CC Role | CC when secondary — may upgrade DRG for principal cardiovascular or systemic diagnosis | CC when secondary — same tier as H34.8110 | CC when secondary — same tier |
| CDI Query Trigger | Note says “CRVO” or “retinal vein occlusion” without specifying edema, NV, or stability | Note says “ischemic CRVO,” “CRVO with NVI/NVD/NVE” without explicit neovascularization terminology | Note says “resolved” or “treated” without confirming absence of both edema and neovascularization |
CDI Trigger
Documentation stating only “retinal vein occlusion,” “CRVO,” or “central retinal vein occlusion, right eye” is insufficient for 7th-character assignment. The medical record must explicitly identify the current clinical state: macular edema (by OCT measurement or clinical description), retinal neovascularization (by fundus exam or FA), or stability. A compliant CDI query should be submitted whenever documentation does not unambiguously support one of the three 7th-character options — the coder may not interpret OCT measurements as a physician diagnosis.
Manifestations & Symptom Burden
- Acute painless central visual acuity loss — typically sudden onset; severity ranges from mild blur to counting-fingers vision depending on degree of macular edema and underlying retinal ischemia.
- Macular edema on SD-OCT — the defining manifestation for H34.8110; measured as central subfield thickness (CST) typically >250–300 µm; cystoid intraretinal spaces, subretinal fluid, and diffuse thickening are characteristic morphologic patterns.
- Diffuse retinal hemorrhage — flame-shaped hemorrhages in the nerve fiber layer and dot/blot hemorrhages in all four quadrants; pathognomonic for CRVO on fundus examination and absent in BRVO (sectoral distribution).
- Disc edema and venous dilation/tortuosity — the optic disc appears swollen with congested, tortuous retinal veins in the acute phase; findings gradually resolve over weeks to months.
- Risk of neovascular complications — if ischemia is significant, development of iris or angle neovascularization (NVI/NVA), neovascular glaucoma (H40.5110), vitreous hemorrhage (H43.11), or tractional retinal detachment may follow weeks to months after initial occlusion if untreated.
Tip
A documented CST measurement (e.g., “central subfield thickness 412 µm by SD-OCT”) in the clinical note is the single strongest documentation element supporting H34.8110 assignment and surviving payer audit. It objectively confirms active macular edema, quantifies disease severity, establishes the baseline for treatment response monitoring, and supports anti-VEGF or steroid implant authorization. When an OCT is performed, the CST value and the interpreting physician’s documented impression should both appear in the encounter record.
💰 HCC Risk Adjustment
| Field | Value |
|---|---|
| HCC Category (CMS-HCC V28) | Not HCC-Mapped — verify against CMS-HCC V28 ICD-10-CM mapping file (PY2026) |
| RAF Contribution | None (verify annually) |
| Condition Family / Hierarchy | N/A |
| V28 Constraining Group | N/A |
ICD-10 CM H34.8110 does not map to an HCC under the CMS-HCC V28 model, which is fully operative for Medicare Advantage payment year 2026 at 100% V28 weighting. Retinal vascular occlusions as a category were not included in V28’s HCC structure, meaning this code generates no RAF score contribution for MA plans. This should not reduce documentation intensity — the systemic conditions that precipitate CRVO (hypertension, diabetes mellitus, hypercoagulable disorders) may independently risk-adjust under their own HCC categories and must be coded completely and specifically to reflect true patient complexity. Verify all HCC assignments annually against the current CMS-HCC V28 ICD-10-CM crosswalk file, as the code universe is subject to update with each payment year rule.
🏥 MS-DRG Assignment
| Field | Value |
|---|---|
| MDC | MDC 02 — Diseases and Disorders of the Eye |
| DRG with MCC or Thrombolytic Agent | DRG 124 — Other Disorders of the Eye with MCC or Thrombolytic Agent |
| DRG without MCC | DRG 125 — Other Disorders of the Eye without MCC |
| CC/MCC Designation (when secondary Dx) | CC — verify against MS-DRG V43.0 CC/MCC exclusion table |
| GMLOS — DRG 124 | (verify against CMS FY2026 IPPS Final Rule, CMS-1808-F) |
| GMLOS — DRG 125 | (verify against CMS FY2026 IPPS Final Rule, CMS-1808-F) |
When H34.8110 is the principal diagnosis on an inpatient admission, the encounter groups to MDC 02 and maps to either DRG 124 (MCC present or thrombolytic agent administered during stay) or DRG 125 (no MCC). Inpatient admission for CRVO-ME as the sole indication is uncommon — intravitreal injection is a same-day outpatient or ASC service — but admission is clinically appropriate when the presentation drives systemic cardiovascular workup (echocardiography, carotid Doppler, hypercoagulable panel, neurology evaluation) or when a complication such as vitreous hemorrhage requires surgical management.
When H34.8110 is a secondary diagnosis, it carries CC designation, which can upgrade the DRG for the principal diagnosis if not excluded by the MS-DRG V43.0 CC/MCC exclusion logic. Always apply the exclusion table before claiming CC credit — certain principal diagnoses exclude co-assigned eye conditions from CC consideration. Note that the MDC 02 DRG 124/125 pair splits only on MCC status; there is no intermediate CC-only DRG tier within this family.
🔗 Related ICD-10-CM Codes
CRVO Siblings — Laterality and Stage Variants
| Code | Description | Relationship |
|---|---|---|
| H34.8111 | Central retinal vein occlusion, right eye, with retinal neovascularization | Same eye, advanced ischemic stage — NVD/NVE is the dominant finding; may co-occur with macular edema |
| H34.8112 | Central retinal vein occlusion, right eye, stable | Same eye, quiescent or post-treatment state — assign when clinician explicitly documents no active edema or neovascularization |
| H34.8120 | Central retinal vein occlusion, left eye, with macular edema | Contralateral laterality sibling — same clinical subtype, left eye |
| H34.8130 | Central retinal vein occlusion, bilateral, with macular edema | Bilateral CRVO with macular edema; uncommon; associated with hypercoagulable states |
| H34.8190 | Central retinal vein occlusion, unspecified eye, with macular edema | Least specific — assign only when laterality is genuinely absent from all documentation; always query provider when possible |
| H34.8310 | Tributary (branch) retinal vein occlusion, right eye, with macular edema | BRVO — occlusion at a vessel bifurcation (not the disc), sectoral hemorrhage; distinct entity with generally better visual prognosis than CRVO |
Systemic Associations and Downstream Complications
| Code | Description | Relationship |
|---|---|---|
| I10 | Essential (primary) hypertension | Most common underlying risk factor for CRVO; code as secondary diagnosis whenever documented as co-existing on the encounter |
| E11.9 | Type 2 diabetes mellitus without complications | Frequent comorbidity; if diabetic macular edema (E11.311) is separately documented in the same eye, a CDI query is needed to determine which condition is driving the macular edema |
| H40.5110 | Glaucoma secondary to other eye disorders, right eye, unspecified stage | Neovascular glaucoma complicating ischemic CRVO — major sequela; assign when documented by the treating clinician |
| H43.11 | Vitreous hemorrhage, right eye | Complication of proliferative CRVO — assign as additional diagnosis when documented on the current encounter |
| G45.3 | Amaurosis fugax | Excludes 1 relationship — mutually exclusive with CRVO codes; see Excludes section above |
🛠️ Commonly Associated CPT Codes
Note
The CPT codes below represent outpatient procedures commonly associated with H34.8110 management. In the inpatient facility setting, the corresponding interventions are reported with ICD-10-PCS codes (see Crosswalk section). These CPT codes appear in outpatient and professional fee records that may accompany or precede an inpatient encounter and are relevant to CDI, auditing, and cross-setting clinical narrative.
| CPT Code | Description | Billing Notes |
|---|---|---|
| 67028 | Intravitreal injection of a pharmacologic agent (separate procedure) | Primary outpatient treatment for CRVO-ME; billed with a drug J-code (e.g., J0178 for aflibercept, J2778 for ranibizumab — verify J-code validity for current year); global period 000 (same day); use modifier RT for right eye |
| 92250 | Fundus photography with interpretation and report | Baseline documentation of retinal hemorrhage pattern and disc appearance; periodically thereafter to track disease course |
| 92134 | Scanning computerized ophthalmic diagnostic imaging, posterior segment; with interpretation and report (OCT macula) | Essential for measuring CST, confirming macular edema diagnosis, and monitoring treatment response; verify code validity against current AMA CPT year |
| 92235 | Fluorescein angiography (includes multiframe imaging) with interpretation and report | Used to classify CRVO as ischemic vs. non-ischemic by quantifying capillary non-perfusion; guides panretinal photocoagulation decisions; verify code number against current AMA CPT year |
| 67210 | Destruction of localized lesion of retina (one or more sessions); photocoagulation | Panretinal photocoagulation (PRP) indicated for ischemic CRVO with documented neovascularization (H34.8111); not indicated for macular edema alone — a diagnosis of H34.8110 will not typically support a 67210 claim without neovascularization documentation |
NCCI Bundling Considerations
CPT 67028 (intravitreal injection) and 92134 (OCT posterior segment) performed on the same date present a frequent NCCI bundling question. 92134 performed as part of the standard pre-injection assessment may be subject to bundling under certain payer policies unless documented as a distinct medically necessary diagnostic service beyond routine pre-procedure monitoring. 92235 (fluorescein angiography) and 67028 are generally separately reportable when performed on different dates or when FA is performed for a distinct diagnostic purpose (ischemia staging). Always review current NCCI edits and MAC-specific ophthalmic service policies; carrier local coverage determinations (LCDs) for anti-VEGF therapy frequently specify which imaging codes are separately payable on the same day as an injection.
🔬 ICD-10-PCS Crosswalk
Note
When treatment for CRVO with macular edema is performed during an inpatient admission, ICD-10-PCS procedure codes are required on the facility claim. The most common inpatient procedure is intravitreal injection of a pharmacologic agent, captured under PCS Section 3 (Administration). Importantly, PCS Section 3 body part C (Eye) does not distinguish between right and left eye — laterality is encoded only in the diagnosis code (H34.8110 for right eye). When bilateral injections are performed during the same operative session, assign two separate PCS codes — one for each eye — using the same code string.
| PCS Code | Full Description | Applicable Agent / Clinical Use |
|---|---|---|
3E0C3GC | Introduction of Other Therapeutic Substance into Eye, Percutaneous Approach | Intravitreal anti-VEGF agents (bevacizumab, ranibizumab, aflibercept, brolucizumab, faricimab); “Other Therapeutic Substance” is the correct substance character for anti-VEGF biologics |
3E0C33Z | Introduction of Anti-inflammatory into Eye, Percutaneous Approach | Intravitreal corticosteroids: dexamethasone implant (Ozurdex), triamcinolone acetonide, fluocinolone acetonide (Iluvien) |
3E0C3GC | Same code — see above | Note: PCS does not distinguish between individual anti-VEGF agents within the current Administration table; all map to the same 7-character code |
PCS Character Analysis — 3E0C3GC
| Position | Character | Value | Definition |
|---|---|---|---|
| 1 | Section | 3 | Administration |
| 2 | Body System | E | Physiological Systems and Anatomical Regions |
| 3 | Root Operation | 0 | Introduction (putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products) |
| 4 | Body Part | C | Eye |
| 5 | Approach | 3 | Percutaneous (intravitreal needle injection through the pars plana) |
| 6 | Substance | G | Other Therapeutic Substance |
| 7 | Qualifier | C | Other Substance |
PCS Root Operation: Introduction vs. Irrigation
- Use Introduction (0) —
3E0C3GCor3E0C33Z— when the procedure involves placing a new pharmacologic agent into the vitreous cavity (anti-VEGF, steroid, antibiotic for endophthalmitis treatment).- Use Irrigation (1) — Section 3, Root Operation 1 — when the procedure involves flushing or washing the vitreous or anterior chamber with a solution (e.g., balanced salt solution, intracameral irrigant).
- PCS has no bilateral modifier equivalent in the Administration section — when injections are performed in both eyes at the same operative session, assign two separate
3E0C3GCcodes, one for each eye; this is consistent with ICD-10-PCS Official Guidelines Section B3.2 (multiple procedures).
💊 Coding Scenarios and Examples
Scenario 1 — Inpatient: H34.8110 as Secondary CC on Cardiovascular Admission
Clinical Vignette: A 68-year-old male with a history of hypertension, atrial fibrillation, and hyperlipidemia is admitted for hypertensive urgency (blood pressure 196/114 mmHg). Ophthalmology is consulted for blurred vision reported in the right eye. Dilated fundus exam reveals diffuse retinal hemorrhage in all four quadrants, optic disc edema, and dilated tortuous veins consistent with CRVO. SD-OCT demonstrates a central subfield thickness of 389 µm with cystoid intraretinal fluid. The ophthalmologist documents in the assessment: “Central retinal vein occlusion, right eye, with macular edema.” No inpatient retinal procedure is performed; outpatient anti-VEGF injection is planned. The principal diagnosis is hypertensive urgency.
| Field | Code | Rationale |
|---|---|---|
| PDx | I10 | Hypertensive urgency — principal reason for admission; drives the DRG grouping |
| SDx | H34.8110 | CRVO right eye with macular edema — documented comorbidity on this encounter; qualifies as CC when secondary; verify against MS-DRG V43.0 CC/MCC exclusion table to confirm no exclusion applies |
Note
H34.8110 as a secondary diagnosis carries CC designation, which may improve the DRG grouping for the principal cardiovascular diagnosis. No PCS code is required on this encounter because no retinal procedure was performed during the admission. The ophthalmology consult documentation supporting macular edema (fundus exam findings + CST measurement) must be present in the medical record to support the secondary diagnosis assignment.
Scenario 2 — Inpatient: H34.8110 as Principal Diagnosis — Systemic Workup Admission with Procedure
Clinical Vignette: A 54-year-old female with no prior ocular history presents to the emergency department with sudden painless vision loss in the right eye noted on waking, documented as 20/200 Snellen. Ophthalmology confirms CRVO on exam; SD-OCT demonstrates a CST of 498 µm. The attending physician admits her for urgent systemic cardiovascular and hypercoagulable workup. Carotid Doppler reveals significant right-side carotid stenosis. On hospital day 2, the retina service performs an intravitreal injection of aflibercept 2 mg into the right eye. Hypertension is documented as a comorbidity.
| Field | Code | Rationale |
|---|---|---|
| PDx | H34.8110 | CRVO right eye with macular edema — principal reason for admission per attending documentation; all other workup is in response to this diagnosis |
| SDx | I10 | Essential hypertension — documented comorbidity; separately codeable per ICD-10-CM Official Guidelines Section I.C |
| PCS | 3E0C3GC | Introduction of other therapeutic substance (aflibercept = anti-VEGF biologic) into eye, percutaneous approach — intravitreal injection performed during admission; required on facility claim |
Note
With H34.8110 as the principal diagnosis, the encounter groups to MDC 02 → DRG 124 (if an MCC is present) or DRG 125 (without MCC). I10 does not qualify as an MCC on most encounters; review the current MS-DRG V43.0 MCC table to confirm. The DRG 124/125 split is MCC-only — there is no intermediate CC-tier DRG within this family, so H34.8110’s own CC designation is only relevant when it is a secondary diagnosis, not the principal.
Scenario 3 — CDI Query: Documentation Insufficient for 7th-Character Assignment
Clinical Vignette: A 72-year-old patient with type 2 diabetes mellitus and hypertension is admitted for a hip fracture following a fall. Ophthalmology is consulted for right eye blur; the consult note states “History of CRVO, right eye. Patient on monthly anti-VEGF injections. OCT macula today: CST 284 µm.” The assessment reads: “CRVO, right eye, continued treatment.” The note does not explicitly state “macular edema,” “neovascularization,” or “stable.” CST of 284 µm is above the standard normal threshold (≤250 µm) but no physician-documented clinical interpretation of the OCT is present.
| Field | Status | Rationale |
|---|---|---|
| PDx | Assign per hip fracture — not eye-related | CRVO is a secondary diagnosis; principal diagnosis is the hip fracture |
| Proposed SDx | H34.8110 (pending query) | OCT CST of 284 µm is consistent with macular edema, but physician has not explicitly documented “macular edema” in the assessment — coder may not independently interpret the measurement |
| Alternative SDx | H34.8112 (if query returns “stable”) | If query confirms CRVO is currently stable on treatment with no active macular edema, this code applies |
Note
CDI Query Standard: Per ICD-10-CM Official Guidelines Section I.B, code assignment must be based on physician documentation; coders may not independently interpret diagnostic test results (including OCT measurements) as equivalent to a physician diagnosis. A compliant AHIMA/ACDIS-format query should read: “The ophthalmology consult for the right eye documents a central subfield thickness (CST) of 284 µm on today’s OCT. Can you clarify the current clinical status of the right eye CRVO as: (a) with macular edema, (b) with retinal neovascularization, or (c) stable? This clarification is needed for accurate ICD-10-CM code assignment.” Do not assign H34.8110 or H34.8112 without the query response.
⚠️ Coding Pitfalls and Tips
-
Submitting the non-billable parent code H34.811: H34.811 (Central retinal vein occlusion, right eye) was converted to a non-billable parent in FY2017 when the 7th character disease-state axis was added. Submitting H34.811 will generate a claim rejection. Ensure all encoders, charge capture tools, and problem list templates in the facility have been updated to surface only the 7-character codes (H34.8110, H34.8111, H34.8112); legacy systems may still default to the 6-character string.
-
Confusing CRVO (H34.8110) with BRVO (H34.8310): CRVO involves occlusion at the lamina cribrosa, producing diffuse hemorrhage in all four retinal quadrants with disc involvement and a typically worse visual prognosis. BRVO involves occlusion at a vessel bifurcation, producing sectoral hemorrhage in one quadrant only, and generally carries a better prognosis. The fundus photograph and clinical note will clearly distinguish the two — these are separate code families, and a BRVO coded as CRVO (or vice versa) constitutes a reportable coding error. Do not assign H34.8110 solely based on a generic “retinal vein occlusion” note without confirming the central versus branch distinction.
-
Inferring the 7th character from OCT measurements without physician documentation: A CST of 290 µm on OCT does not authorize the assignment of H34.8110 without explicit physician documentation of “macular edema.” Per ICD-10-CM Official Guidelines Section I.B, the coder may not independently interpret diagnostic findings. Conversely, a normal-range CST does not justify H34.8112 (stable) without a physician-documented statement of stability or resolution. In either case, if the documentation is ambiguous, a CDI query is the required and compliant next step.
-
Assigning H34.8110 and E11.311 simultaneously without clinical distinction: Type 2 diabetes mellitus with diabetic macular edema (E11.311) and CRVO-associated macular edema (H34.8110) are pathophysiologically distinct entities that can co-exist in the same eye. When both are documented, both may be coded; sequence based on the reason for the encounter. However, if the documentation is ambiguous about which condition is driving the macular edema, a CDI query clarifying the primary etiology is required before assigning both codes — assigning both without clinical support constitutes overcoding.
-
Defaulting to H34.8190 (unspecified eye) without exhausting available sources: The unspecified eye code should be assigned only when laterality is genuinely absent from all available documentation across the entire health record — problem list, ophthalmology consult, imaging reports, operative reports, and nursing notes. In practice, fundus examination and OCT reports invariably specify laterality; the unspecified code is almost never justified. If the discharge summary omits the side but the ophthalmology consult clearly documents “right eye,” use H34.8110. Query the provider when laterality is inconsistent across the record.
-
Omitting systemic comorbidities as secondary diagnoses: CRVO is a vascular event strongly linked to systemic conditions that independently affect patient risk and resource utilization. Failure to code documented hypertension (I10), diabetes (E11.9), or other co-existing conditions as secondary diagnoses results in an incomplete clinical picture, misses CC credit opportunities for the facility claim, and may generate a CDI query from the MAC or payer. Code all conditions that are documented as managed, monitored, or affecting the patient’s care during the admission, per ICD-10-CM Official Guidelines Section I.C and the UHDDS definition of “other diagnoses.”